鸦胆子油联合吉西他滨和顺铂治疗晚期非小细胞肺癌的临床观察
发布时间：2019-06-02 08:48
【摘要】：目的:观察鸦胆子油联合吉西他滨和顺铂治疗晚期非小细胞肺癌(NSCLC)的临床效果及安全性。方法:选取黄冈市中医医院2014年2月-2016年1月收治的晚期NSCLC患者131例,按照随机数字表法分为观察组(71例)和对照组(60例)。对照组患者给予注射用盐酸吉西他滨(第1、8天)+顺铂注射液(第2天),每21 d重复1次,连续2次为1个疗程;观察组患者在此基础上给予鸦胆子油口服乳液20 m L,po,2~3次/d,连续14 d(于每次化疗前3 d开始给药)。两组患者均治疗87 d,并随访至2016年6月1日。观察两组患者临床疗效、T细胞亚群(CD3+、CD4+、CD8+)水平和生存时间,对生存时间进行单因素和多因素分析,并记录不良反应发生情况。结果:观察组患者的总有效率(32.39%)高于对照组(25.00%),但差异无统计学意义(P0.05)。治疗前,两组患者CD3+、CD4+和CD8+水平比较,差异均无统计学意义(P0.05)。治疗后,观察组患者CD3+、CD4+水平较治疗前明显升高,CD8+水平明显降低,且与同期对照组比较,差异均有统计学意义(P0.05)。观察组患者失访4例,对照组失访3例。观察组患者生存时间[(14.02±4.10)个月]较对照组[(13.21±5.22)个月]长,但差异无统计学意义(P0.05)。单因素分析结果显示,70岁患者的生存时间明显长于≥70岁患者,合并胸腔积液患者的生存时间明显短于无胸腔积液患者,差异均有统计学意义(P0.05)。多因素分析结果显示,是否合并胸腔积液和年龄是晚期NSCLC患者生存时间的影响因素(比值比分别为1.685、0.647,P分别为0.012、0.043)。观察组患者的不良反应发生率(50.70%)与对照组(53.33%)比较,差异无统计学意义(P0.05)。结论:鸦胆子油联合吉西他滨和顺铂治疗晚期NSCLC,虽不能明显提高疗效,但能提高机体免疫功能。是否合并胸腔积液和年龄是晚期NSCLC患者生存时间的影响因素。
[Abstract]:Objective: to observe the clinical efficacy and safety of Brucea javanica oil combined with gemcitabine and DDP in the treatment of advanced non-small cell lung cancer (NSCLC). Methods: from February 2014 to January 2016, 131 patients with advanced NSCLC were randomly divided into observation group (71 cases) and control group (60 cases). The patients in the control group were given gemcitabine hydrochloric acid injection (day 1 and day 8), repeated every 21 days, twice as a course of treatment. On this basis, the patients in the observation group were given Brucea javanica oil oral emulsion 20 mL, 2 times 3 times a day for 14 days (starting 3 days before each chemotherapy). The patients in both groups were treated for 87 days and followed up until June 1, 2016. The clinical efficacy, CD3, CD4, CD8 level and survival time of the two groups were observed, and the survival time was analyzed by univariate and multivariate analysis, and the occurrence of adverse reactions was recorded. Results: the total effective rate of the patients in the observation group (32.39%) was higher than that in the control group (25.00%), but the difference was not statistically significant (P 0.05). Before treatment, there was no significant difference in the levels of CD3, CD4 and CD8 between the two groups (P 0.05). After treatment, the levels of CD3 and CD4 in the observation group were significantly higher than those before treatment, and the levels of CD8 were significantly lower than those in the control group at the same time (P 0.05). There were 4 cases of lost follow-up in the observation group and 3 cases in the control group. The survival time of the patients in the observation group [(14.02 卤4.10) months] was longer than that in the control group [(13.21 卤5.22) months], but the difference was not statistically significant (P 0.05). The results of univariate analysis showed that the survival time of patients aged 70 years old was significantly longer than that of patients 鈮，
本文编号：2490970
[Abstract]:Objective: to observe the clinical efficacy and safety of Brucea javanica oil combined with gemcitabine and DDP in the treatment of advanced non-small cell lung cancer (NSCLC). Methods: from February 2014 to January 2016, 131 patients with advanced NSCLC were randomly divided into observation group (71 cases) and control group (60 cases). The patients in the control group were given gemcitabine hydrochloric acid injection (day 1 and day 8), repeated every 21 days, twice as a course of treatment. On this basis, the patients in the observation group were given Brucea javanica oil oral emulsion 20 mL, 2 times 3 times a day for 14 days (starting 3 days before each chemotherapy). The patients in both groups were treated for 87 days and followed up until June 1, 2016. The clinical efficacy, CD3, CD4, CD8 level and survival time of the two groups were observed, and the survival time was analyzed by univariate and multivariate analysis, and the occurrence of adverse reactions was recorded. Results: the total effective rate of the patients in the observation group (32.39%) was higher than that in the control group (25.00%), but the difference was not statistically significant (P 0.05). Before treatment, there was no significant difference in the levels of CD3, CD4 and CD8 between the two groups (P 0.05). After treatment, the levels of CD3 and CD4 in the observation group were significantly higher than those before treatment, and the levels of CD8 were significantly lower than those in the control group at the same time (P 0.05). There were 4 cases of lost follow-up in the observation group and 3 cases in the control group. The survival time of the patients in the observation group [(14.02 卤4.10) months] was longer than that in the control group [(13.21 卤5.22) months], but the difference was not statistically significant (P 0.05). The results of univariate analysis showed that the survival time of patients aged 70 years old was significantly longer than that of patients 鈮，
本文编号：2490970
本文链接：https://www.wllwen.com/yixuelunwen/zlx/2490970.html
